PCM
TGTX icon

Prelude Capital Management’s TG Therapeutics TGTX Stock Holding History

Prelude Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-57,497
Closed -$1.34M – 1563
2024
Q3 		$1.34M Sell
57,497
-10,139
-15% -$221K 0.08% 308
2024
Q2 		$1.2M Buy
67,636
+12,036
+22% +$192K 0.08% 282
2024
Q1 		$846K Buy
55,600
+6,800
+14% +$108K 0.04% 439
2023
Q4 		$834K Sell
48,800
-9,952
-17% -$116K 0.06% 338
2023
Q3 		$491K Buy
58,752
+49,430
+530% +$689K 0.03% 478
2023
Q2 		$232K Buy
+9,322
New +$241K 0.02% 780
2023
Q1 		– Sell
-37,127
Closed -$439K – 1461
2022
Q4 		$439K Sell
37,127
-900
-2% -$6.53K 0.02% 619
2022
Q3 		$225K Sell
38,027
-1,947
-5% -$12.8K 0.01% 1025
2022
Q2 		$170K Sell
39,974
-1,677
-4% -$10.5K ﹤0.01% 1329
2022
Q1 		$396K Buy
41,651
+1,823
+5% +$21.1K 0.01% 970
2021
Q4 		$757K Buy
39,828
+846
+2% +$22K 0.02% 762
2021
Q3 		$1.3M Buy
+38,982
New +$1.21M 0.03% 458
2019
Q4 		– Sell
-100
Closed -$760 – 2245
2019
Q3 		$1K Buy
+100
New +$697 ﹤0.01% 1646
2019
Q1 		– Sell
-73
Closed -$395 – 2172
2018
Q4 		$0 Buy
+73
New +$363 ﹤0.01% 2151
2018
Q3 		– Sell
-78
Closed -$1K – 2033
2018
Q2 		$1K Buy
+78
New +$1.07K ﹤0.01% 1610
2014
Q4 		– Sell
-2,007
Closed -$21K – 2147
2014
Q3 		$21K Buy
2,007
+1,582
+372% +$14.7K ﹤0.01% 1730
2014
Q2 		$4K Sell
425
-8,580
-95% -$54.9K ﹤0.01% 1850
2014
Q1 		$62K Buy
+9,005
New +$53.3K 0.01% 1213

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Prelude Capital Management's TGTX Position: Q4 2024 in Review

Prelude Capital Management sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 57,497 shares — an estimated $1.34M sold.

Prelude Capital Management first reported a position in TGTX in Q1 2014 and held it in 18 quarters. The position peaked at $1.34M in Q3 2024. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Prelude Capital Management reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 57,497 TG Therapeutics shares in Q4 2024, an estimated $1.34M.
  • Prelude Capital Management first reported a position in TG Therapeutics in Q1 2014 and held it in 18 quarters.
  • Prelude Capital Management's TG Therapeutics position peaked at $1.34M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.